- Company
- The Effects and Challenges of Vitrakvi
- by Jul 20, 2021 05:46am
- Bayer's "Vitrakvi" has been able to treat cancer patients who are positive for NTRK gene fusion, regardless of cancer type. The NTRK gene plays an essential role in the physiology, development and function of the nervous system through the TRK protein, which causes problems when unrelated genes are combined. This phenomenon, called NTRK
- Company
- ‘Tagrisso’ tenaciously attempts reimb. for 1st line NSCLC
- by Eo, Yun-Ho Jul 19, 2021 10:34am
- AstraZeneca Korea is attempting to receive insurance benefits for ‘Tagrisso’ once again after modifying its reimbursement standards. Industry officials said that AstraZeneca Korea had recently reapplied for expansion of insurance benefit for its 3rd generation EGFR TKI Tagrisso (osimertinib) to first-line treatment in non-small cell lu
- Company
- Prolonged Galvus patent dispute… results to come next year?
- by Kim, Jin-Gu Jul 19, 2021 05:56am
- The patent dispute surrounding Novartis’ anti-diabetic DPP-4 inhibitor ‘Galvus (vildagliptin)’ may be prolonged and not be concluded within this year. With the substance patent of the said product to expire in March of next year, the benefits of early release will disappear for generic companies if the ruling comes after then. However, gen
- Company
- Emtuen became the largest shareholder of SillaJen
- by An, Kyung-Jin Jul 19, 2021 05:56am
- SillaJen said that Emtuen paid ￦60 billion for 18.75 million shares. Emtuen will become SillaJen's new largest shareholder starting with the payment, seeking to normalize its management and strengthen its expertise in bio-industry companies. On the 13th of next month, SillaJen will hold an extraordinary shareholders' meeting at the Korea
- Company
- ↑38% of drug exports in the first half
- by Kim, Jin-Gu Jul 19, 2021 05:56am
- In the first half of the year, Korea's pharmaceutical exports recorded about ￦4.5 trillion. There is a possibility that it will surpass ￦10 trillion within this year. In particular, exports of medicines to Germany have increased significantly. In the first half of this year alone, more than ￦1.5 trillion was exported to Germany. Germany's sh
- Policy
- Aduhel has been applied for permission in Korea
- by Lee, Tak-Sun Jul 19, 2021 05:56am
- Recently, Aduhel (Aducanumab), a new drug for Alzheimer's disease approved by the U.S. Food and Drug Administration (FDA), has applied for permission in Korea. Aduhel is a new drug for Alzheimer's disease approved by the U.S. FDA in 18 years, the first drug to target the amino acid peptide β-amyloid known to be involved in the disease.
- Company
- Onivyde is expected to be eligible for insurance coverage
- by Eo, Yun-Ho Jul 16, 2021 05:54am
- The new pancreatic cancer drug Onivyde is expected to be listed on the insurance benefit. According to the industry, Servier recently concluded a negotiation with the NHIS for the listing of Onivyde(Irinotecan HCl). As a result, it is expected that new insurance benefits will be available in pancreatic cancer treatment. Onivyde is elig
- Policy
- Once 'out of stock' Bayer Aspirin 100mg to be discontinued
- by Lee, Tak-Sun Jul 16, 2021 05:54am
- Bayer decided to discontinue domestic supply of its antipyretic analgesic, ‘Bayer Aspirin 100mg.’ Despite the company’s explanation that the decision was made due to poor sales, the pharmacys’ eyes are not so kind on the company's decision as they have suffered shortages of stock issues regarding the product. According to the Ministry
- Policy
- 2nd AZ·Pfizer·Moderna shot prevents variants by 80%
- by Lee, Hye-Kyung Jul 16, 2021 05:54am
- Study results on the preventive effect of the AstraZeneca, Pfizer, and Moderna vaccine against variants showed that the vaccines had a preventive effect of over 80% after completing the two-dose regimen. The prevention effect was greater against the Alpha variant than the Delta. In preventing symptomatic infections, the vaccines had a sim
- Company
- SMA tx Evrysdi has been applied for insurance benefits
- by Jul 16, 2021 05:54am
- Roche's Evrysdi, the second treatment for spinal muscular atrophy (SMA) in Korea, began the process of registering insurance benefits eight months after approval. According to the pharmaceutical industry on the 15th, Roche Korea applied to the HIRA earlier this month for the registration of the oral SMA treatment Evrysdi(Risdiplam). Evr
